Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.
In a controlled double blind trial the symptomatic effect of the calcium channel blocker nisoldipine was assessed in 19 patients with idiopathic Raynaud's phenomenon. Nisoldipine significantly reduced the frequency of attacks (p less than 0.05), whilst having a non-significant tendency (p less than 0.10) to reduce the severity of attacks. Side-effects were uncommon. It is concluded that nisoldipine is a promising agent for the symptomatic treatment of idiopathic Raynaud's phenomenon.
D000328:Adult; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015737:Nisoldipine; D011897:Random Allocation; D011928:Raynaud Disease / Q000188:drug therapy*
D002121:Calcium Channel Blockers; D015737:Nisoldipine; D009543:Nifedipine